The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Recombinant factor IX Fc for the treatment of hemophilia B
In this video, Amy Shapiro, MD, Indiana University Hemophilia Center, Indianapolis, IN, briefly discusses the use of recombinant factor IX Fc for the treatment of patients with hemophilia B, outlining its dosing schedule and efficacy. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Recombinant factor IX Fc is a long-lasting factor IX concentrate for patients with hemophilia B. It is administered on a schedule either for treatment of bleeding episodes or for prophylaxis. It can be administered once weekly or at extended intervals based upon patient preference and individual pharmacokinetics. Its data in terms of safety and effectiveness are excellent, reported in different age groups and has been shown to be effective also in the surgical setting in terms of control of bleeding and good surgical outcomes...
Recombinant factor IX Fc is a long-lasting factor IX concentrate for patients with hemophilia B. It is administered on a schedule either for treatment of bleeding episodes or for prophylaxis. It can be administered once weekly or at extended intervals based upon patient preference and individual pharmacokinetics. Its data in terms of safety and effectiveness are excellent, reported in different age groups and has been shown to be effective also in the surgical setting in terms of control of bleeding and good surgical outcomes.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Plasminogen Deficiency Foundation: Membership on an entity’s Board of Directors or advisory committees; Regeneron: Research Funding; Sanofi-Genzyme/Bioverativ: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding, Speakers Bureau; Hema Biologics: Membership on an entity’s Board of Directors or advisory committees; Novo Nordisk: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding, Speakers Bureau; Pfizer: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Kedrion Biopharma: Consultancy, Honoraria, Research Funding, Speakers Bureau; Takeda Pharmaceuticals: Research Funding; Pharmacosmos A/S: Research Funding; Cantessa Pharmaceuticals/ApcinteX Ltd.: Research Funding; Novo Nordisk Haemophilia Foundation: Membership on an entity’s Board of Directors or advisory committees; Be Biopharma: Membership on an entity’s Board of Directors or advisory committees; Genentech/Roche: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding, Speakers Bureau; Indiana Hemophilia & Thrombosis Center, Inc.: Current Employment; BioMarin: Membership on an entity’s Board of Directors or advisory committees; NHPCC: Other: Medical Director.
